Home » Topics » BioWorld Science

BioWorld Science
RSS

ReNeuron provides update for hRPC therapy candidate study

June 10, 2021

Shoreline and BeiGene collaborate to develop and commercialize NK-based cell therapies

June 10, 2021

Urinary CCL5 mRNA is predictive of diabetic nephropathy progression

June 10, 2021

Lilly's SERD LY-3484356 well tolerated in first-in-human study

June 10, 2021

Peptide-drug conjugate PEN-221 demonstrates efficacy in patients with GI neuroendocrine tumors

June 10, 2021

Gilead discovers Mcl-1 inhibitors

June 10, 2021

New tucaresol prodrugs discovered at Beyondspring Pharmaceuticals

June 10, 2021

Bayer patents prostaglandin E2 receptor EP3 subtype antagonists

June 10, 2021

Yuhan Corp. describes compositions including GDF15 variants

June 10, 2021

New GLP-1 receptor agonists identified at ILDONG Pharmaceutical

June 10, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...